POSTmark Autologous: The Case For Manufacturing Continuity

Transitioning autologous cell therapies from early research into cGMP manufacturing presents significant operational hurdles. Traditional development models often treat research, clinical translation, and commercial production as separate stages. Handing off a process developed with research-grade materials and manual protocols frequently uncovers hidden gaps in scalability, leading to unpredicted material substitutions, altered cell phenotypes, and costly comparability studies that delay clinical trial initiation. Establishing environmental, operational, and analytical continuity from day one mitigates these translational risks. Utilizing mirrored technological platforms, automated closed processing systems, and qualified analytical methods across both development and clinical phases eliminates the variance typical of classical technology transfers.

Learn how this unified framework enables rapid multi-day release workflows and builds a traceable, historical data package to satisfy Chemistry, Manufacturing, and Controls requirements.